Anti-angiogenic therapies for metastatic colorectal cancer: Current and future perspectives
作者： Inês Marques , António Araújo , Ramon Andrade de Mello , None
关键词:
摘要: Colorectal cancer (CRC) is the fourth most commonly diagnosed and second leading cause of death in both men women United States, with about 142820 new cases 50830 deaths expected 2013. Metastatic disease (mCRC) remains a challenge for oncologists worldwide due to its potential comorbidities. Recently, chemotherapy regimens containing 5-fluorouracil, leucovorin, oxaliplatin irinotecan combinations are standard care metastatic disease. Currently, biological therapies involving vascular endothelial growth factor epidermal receptor pathways, such as bevacizumab cetuximab, have emerged good option improving mCRC patient survival. Now, aflibercept plus has also been approved line regimen patients. Our review will discuss novel drugs their indications patients bring future perspectives this regard.
sci-hub.st 参考文章(106)
Joshua Ö. Haznedar, Juthamas Sukbuntherng, Katherine G. Moss, Tinya J. Abrams, Julie M. Cherrington, Randall E. Schreck, Jeremy Carver, Cho Tang, Dirk B. Mendel, Gerald McMahon, James G. Christensen, Lesley J. Murray, Leslie B. Lee, Sharianne G. Louie, Emily Chan, Sheri Shirazian, Todd Miller, Guangmin Li, Theresa J. Ngai, Robert A. Blake, A. Douglas Laird, Xiaohua Xin, Li Sun, In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors Determination of a Pharmacokinetic/Pharmacodynamic Relationship Clinical Cancer Research. ,vol. 9, pp. 327- 337 ,(2003)
Maria Ignez Braghiroli, Jorge Sabbaga, Paulo M Hoff, Bevacizumab: overview of the literature Expert Review of Anticancer Therapy. ,vol. 12, pp. 567- 580 ,(2012) , 10.1586/ERA.12.13
Robert J. Cersosimo, Management of advanced colorectal cancer, part 1 American Journal of Health-system Pharmacy. ,vol. 70, pp. 395- 406 ,(2013) , 10.2146/AJHP110532
Jolien Tol, Miriam Koopman, Annemieke Cats, Cees J. Rodenburg, Geert J.M. Creemers, Jolanda G. Schrama, Frans L.G. Erdkamp, Allert H. Vos, Cees J. van Groeningen, Harm A.M. Sinnige, Dirk J. Richel, Emile E. Voest, Jeroen R. Dijkstra, Marianne E. Vink-Börger, Ninja F. Antonini, Linda Mol, Johan H.J.M. van Krieken, Otilia Dalesio, Cornelis J.A. Punt, Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer The New England Journal of Medicine. ,vol. 360, pp. 563- 572 ,(2009) , 10.1056/NEJMOA0808268
K. P. W. J. McAdam, J. Li, J. Knowles, N. T. Foss, C. A. Dinarello, L. J. Rosenwasser, M. J. Selinger, M. M. Kaplan, R. Goodman Tufts, P. N. Herbert, L. L. Bausserman, L. M. Nadler, THE BIOLOGY OF SAA: IDENTIFICATION OF THE INDUCER, IN VITRO SYNTHESIS, AND HETEROGENEITY DEMONSTRATED WITH MONOCLONAL ANTIBODIES Annals of the New York Academy of Sciences. ,vol. 389, pp. 126- 136 ,(1982) , 10.1111/J.1749-6632.1982.TB22131.X
Eric Van Cutsem, Claus-Henning Köhne, István Láng, Gunnar Folprecht, Marek P. Nowacki, Stefano Cascinu, Igor Shchepotin, Joan Maurel, David Cunningham, Sabine Tejpar, Michael Schlichting, Angela Zubel, Ilhan Celik, Philippe Rougier, Fortunato Ciardiello, Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status Journal of Clinical Oncology. ,vol. 29, pp. 2011- 2019 ,(2011) , 10.1200/JCO.2010.33.5091
Marc Peeters, Tim Price, Jean‐Luc Van Laethem, Anti–Epidermal Growth Factor Receptor Monotherapy in the Treatment of Metastatic Colorectal Cancer: Where Are We Today? Oncologist. ,vol. 14, pp. 29- 39 ,(2009) , 10.1634/THEONCOLOGIST.2008-0167
Josep Tabernero, Eric Van Cutsem, Eduardo Díaz-Rubio, Andrés Cervantes, Yves Humblet, Thierry André, Jean-Luc Van Laethem, Patrick Soulié, Esther Casado, Chris Verslype, Javier Sastre Valera, Giampaolo Tortora, Fortunato Ciardiello, Oliver Kisker, Aimery de Gramont, None, Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 25, pp. 5225- 5232 ,(2007) , 10.1200/JCO.2007.13.2183
C. Bokemeyer, I. Bondarenko, J.T. Hartmann, F. de Braud, G. Schuch, A. Zubel, I. Celik, M. Schlichting, P. Koralewski, Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study Annals of Oncology. ,vol. 22, pp. 1535- 1546 ,(2011) , 10.1093/ANNONC/MDQ632
Tara Karnezis, Ramin Shayan, Carol Caesar, Sally Roufail, Nicole C. Harris, Kathryn Ardipradja, You Fang Zhang, Steven P. Williams, Rae H. Farnsworth, Ming G. Chai, Thusitha W.T. Rupasinghe, Dedreia L. Tull, Megan E. Baldwin, Erica K. Sloan, Stephen B. Fox, Marc G. Achen, Steven A. Stacker, VEGF-D Promotes Tumor Metastasis by Regulating Prostaglandins Produced by the Collecting Lymphatic Endothelium Cancer Cell. ,vol. 21, pp. 181- 195 ,(2012) , 10.1016/J.CCR.2011.12.026